AbbVie sued Payer Matrix in May 2023, accusing the specialty-drug advocacy firm of steering insured patients into AbbVie’s charitable assistance program by misrepresenting their coverage. The AbbVie vs. Payer Matrix lawsuit is pending in the United States District Court for the Northern District of Illinois as Case 1:23-cv-02836, and in August 2025 the court allowed several of AbbVie’s claims to move forward into discovery.1Justia Dockets & Filings. AbbVie Inc. v. Payer Matrix, LLC
What Payer Matrix Does
Payer Matrix works with self-insured employer health plans to lower what those plans spend on specialty drugs like Humira. The model starts by reclassifying certain specialty medications as non-standard benefits, so their cost no longer runs through the plan the way ordinary prescriptions do. Once the drug sits outside standard coverage, Payer Matrix helps the affected patient apply to outside sources of funding, including manufacturer-run assistance programs.
The financial mechanics matter to the dispute. The employer stops paying for the drug through its plan. The manufacturer’s charity foundation picks up the medication. Payer Matrix collects a service fee that can reach 25% of the drug’s list price.
What AbbVie Claims
AbbVie’s complaint centers on how patients get through the door of its assistance program. The manufacturer alleges Payer Matrix represents to the AbbVie Patient Assistance Foundation that patients are responsible for 100% of their specialty drug costs, when those same patients are in fact enrolled in comprehensive employer-sponsored insurance.2Justia Law. AbbVie Inc. v. Payer Matrix, LLC – Document 343 According to AbbVie, Payer Matrix fills out application paperwork on patients’ behalf without disclosing its own involvement, which keeps the manufacturer from spotting plans that have been engineered to shed specialty drug coverage.
AbbVie says the result is millions of dollars in free medication going to people who had insurance the entire time. The lawsuit seeks damages and a stop to what AbbVie calls a systematic manipulation of its charitable aid process.
A second theory in the complaint is tortious interference. AbbVie’s assistance program has terms patients must agree to, including financial and insurance-status criteria. AbbVie alleges Payer Matrix induces patients to submit information that violates those terms, breaching the eligibility rules that define who the program is for. The claim frames Payer Matrix as knowingly pushing patients past the program’s stated limits for its own financial gain.
Why Eligibility Matters
The suit turns on who the AbbVie Patient Assistance Foundation is meant to serve. To qualify, patients generally must:2Justia Law. AbbVie Inc. v. Payer Matrix, LLC – Document 343
- Be uninsured or underinsured
- Meet specific financial need or income criteria
- Be a resident of the United States
- Have a valid prescription from a licensed U.S. healthcare provider
AbbVie’s position is that the “uninsured or underinsured” status of Payer Matrix’s referred patients is manufactured rather than real. Because these plans are typically self-insured employer plans governed by ERISA,3U.S. Department of Labor. Employment Law Guide – ERISA the employer has flexibility to define what the plan covers, and AbbVie argues that flexibility is being used to push costs onto a charity fund meant for people with genuine hardship.
Where the Case Stands
Payer Matrix moved to dismiss, arguing AbbVie’s claims were legally insufficient to proceed. In August 2025, the court ruled on that motion and allowed several of AbbVie’s claims to survive.4Justia Law. AbbVie Inc. v. Payer Matrix, LLC – Document 387 The file does not specify which claims were dismissed, if any, or which were allowed to proceed by name.
The case is now in discovery, with both sides exchanging documents and taking depositions focused on how Payer Matrix operates. No trial date has been set. Because alternative funding programs are widely used by self-insured employers to control specialty drug spending, the eventual ruling is expected to affect how similar third-party advocacy models operate.